Literature DB >> 27230620

Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study.

Ja Min Byun1, Young Jin Kim2, Hwi-Joong Yoon3, Si-Young Kim3, Hee-Je Kim4, Jaeho Yoon4, Yoo Hong Min5, Jun-Won Cheong5, Jinny Park6, Jae Hoon Lee6, Dae Sik Hong7, Seong Kyu Park7, Hyeoung-Joon Kim8, Jae-Sook Ahn8, Ho-Jin Shin9, Joo Seop Chung9, Won Sik Lee10, Sang Min Lee10, Yong Park11, Byung Soo Kim11, Je-Hwan Lee12, Kyoo-Hyung Lee12, Chul Won Jung13, Jun Ho Jang13, Woo-Sung Min14, Tae Sung Park15.   

Abstract

The cytogenetic and molecular data is recognized as the most valuable prognostic factor in acute myeloid leukemia (AML). Our aim was to systemically analyze the cytogenetics of Korean AML patients and to compare the cytogenetic profiles of various races to identify possible geographic heterogeneity. We retrospectively reviewed medical records of 2806 AML patients diagnosed at 11 tertiary teaching hospitals in Korea between January 2007 and December 2011. The most common recurrent chromosomal abnormality was t(8;21) (8.8 %, 238/2717), but t(15;17) showed an almost same number (8.6 %,235/2717). Among de novo AML, the most frequent aberrations were t(15;17), observed in 229 (10.7 %). The most common French-American-British (FAB) classification type was M2 (32.2 %), and recurrent cytogenetic abnormalities correlated with the FAB subtypes. Among 283 secondary AML cases, myelodysplastic syndrome was the most common predisposing factor. About 67.1 % of the secondary AML cases were associated with chromosomal aberrations, and chromosome 7 abnormalities (n = 45, 15.9 %) were most common. The incidence of FLT3 internal tandem duplication mutation was relatively low at 15 %. Our study reports certain similarities and differences in comparison to previous reports. Such discrepancies call for extensive epidemiological studies to clarify the role of genetic as well as geographic heterogeneity in the pathogenesis of AML.

Entities:  

Keywords:  Acute myeloid leukemia; Chromosomal abnormalities; Cytogenetics; Population study

Mesh:

Substances:

Year:  2016        PMID: 27230620     DOI: 10.1007/s00277-016-2691-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.

Authors:  Qingxiao Hong; Xiaoying Chen; Huadan Ye; Xiaodong Wu; Xuejing Wang; Lingyan Kong; Yongming Xia; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-03-10       Impact factor: 2.967

2.  Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.

Authors:  Kwai Han Yoo; Hyeoung-Joon Kim; Yoo Hong Min; Dae-Sik Hong; Won Sik Lee; Hee-Je Kim; Ho-Jin Shin; Yong Park; Je-Hwan Lee; Hawk Kim
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

3.  Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.

Authors:  Xiaofei Zhou; Sharon Friedlander; Erik Kupperman; Farhad Sedarati; Shingo Kuroda; Zhaowei Hua; Ying Yuan; Yuka Yamamoto; Douglas V Faller; Kazue Haikawa; Katsuhiko Nakai; Sharon Bowen; Yi Dai; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-02-02       Impact factor: 4.689

4.  MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.

Authors:  Xiaolu Zhang; Bingnan Li; Jingya Yu; Jenny Dahlström; Anh Nhi Tran; Magnus Björkholm; Dawei Xu
Journal:  Ann Hematol       Date:  2017-10-27       Impact factor: 3.673

5.  Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia.

Authors:  Xiaolan Shi; Jiao Li; Liang Ma; Lijun Wen; Qinrong Wang; Hong Yao; Changgeng Ruan; Depei Wu; Xinyou Zhang; Suning Chen
Journal:  Oncol Lett       Date:  2019-03-15       Impact factor: 2.967

6.  Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality.

Authors:  Shinya Rai; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Itaru Matsumura
Journal:  Front Immunol       Date:  2019-01-09       Impact factor: 7.561

7.  Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.

Authors:  Muskan Floren; Sebastian Restrepo Cruz; Christina M Termini; Kristopher D Marjon; Keith A Lidke; Jennifer M Gillette
Journal:  Oncogene       Date:  2020-03-19       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.